VEC.L Regulatory News (VEC)

Vectura Group appoints Kevin Matthews to its Board of Directors

Chippenham, UK - 1 April 2019: Vectura Group plc (LSE: VEC) ("Vectura", the "Group", or the "Company"), an industry-leading inhaled product formulation, device design and development business, is pleased to announce the appointment of Dr Kevin Matthews as an Independent Non-Executive Director of the Company with effect from 29 March 2019. Upon appointment, Kevin will also become a member of the Remuneration Committee.

Kevin has more than 20 years' experience in senior management roles in the chemical, technology and pharmaceutical sectors. He has significant marketing, strategy and management expertise and was, until the end of 2018, Executive Chair of Itaconix plc, an AIM-listed polymers business, having successfully led the organisation as Chief Executive Officer. A Fellow of the Royal Society of Chemistry, Kevin has a strong technical background and has previously held CEO roles at technology companies including Isogenica, a privately-held antibody drug discovery company and Oxonica plc, an advanced materials business. Prior to this he held leadership roles in multinational chemical companies Rhodia S.A, Albright & Wilson plc and ICI.

Kevin is currently a Non-Executive Director on the Board of FTSE SmallCap performance materials business, Low & Bonar plc, where he chairs the Remuneration Committee. He is also an advisor to the Board of the privately held specialty chemicals company, Scott Bader. He served as a Non-Executive Director and Remuneration Committee chair of Elementis plc, a FTSE 250 specialty chemicals business from 2005 to 2014. He also served as a Non-Executive Director of Cellectricon AB, a Swedish biotechnology company dedicated to drug discovery and research in the areas of chronic pain and neurodegenerative disease, from 2011 to 2014.

Bruno Angelici, Chairman of Vectura, commented: 

"I'm delighted to welcome Kevin to the Board of Vectura. Kevin brings highly relevant experience as an independent advisor to companies with his expertise in strategy and business management. His experience of remuneration committee matters will also be an important contribution to the Board."

Commenting on his appointment, Kevin Matthews, said: 

"I am pleased to join the Board of Vectura at this exciting time. I look forward to helping the Board build on the Company's position as a leading specialist medical technology business, providing significant benefits to an increasing number of patients."

There are no additional details to disclose under Listing Rule 9.6.13 (1) to (6) in respect of the appointment of Kevin Matthews.

- Ends -

For more information, please contact:

About Vectura

Vectura is an industry-leading inhaled product formulation, device design and development business offering a uniquely integrated inhaled drug delivery platform. We develop inhalation products to help patients suffering from airways diseases.

Vectura has eight key inhaled, two non-inhaled and ten oral products marketed by partners with growing global royalty streams, and a diverse partnered portfolio of drugs in clinical development. Our partners include Hikma, Novartis, Sandoz, Mundipharma, Kyorin, Baxter, GSK, UCB, Bayer, Chiesi, Almirall, Janssen, Dynavax and Tianjin KingYork.

Vectura's strategy is to fully leverage its differentiated technology and skills, maximising value by enhancing the delivery and performance of inhaled products and through the development of high-quality generic alternatives to branded therapies.

For further information, please visit Vectura's website at www.vectura.com.